[{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","commit":"1fcb3c8eab","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on the remaining institutions and thirty more companies","file":"src/data/companies.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.corcept.com\" }]"}]},{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"tldr","before":"\"Cortisol-modulation company whose relacorilant was approved in ovarian cancer in 2026.\"","after":"\"Corcept is a cortisol-modulation company whose relacorilant was approved in ovarian cancer in 2026.\""}]}]